Prehospital antiplatelets improve graft intervention outcomes

January 28, 2013
Prehospital antiplatelets improve graft intervention outcomes
Prehospital use of antiplatelet therapy, either aspirin/clopidogrel or dual antiplatelet therapy, is associated with a lower incidence of major adverse cardiac events after saphenous vein graft intervention, according to research published in the Jan. 15 issue of The American Journal of Cardiology.

(HealthDay)—Prehospital use of antiplatelet therapy, either aspirin/clopidogrel or dual antiplatelet therapy (DAPT), is associated with a lower incidence of major adverse cardiac events after saphenous vein graft (SVG) intervention, according to research published in the Jan. 15 issue of The American Journal of Cardiology.

Ralf E. Harskamp, M.D., of the University of Amsterdam, and colleagues evaluated the association between prehospital antiplatelet regimens and outcome for 225 patients (87 percent men; mean age, 70 years) who underwent SVG intervention.

Prior to the intervention, 9.4 percent of patients had not received any antiplatelet therapy, 45.3 percent received aspirin/clopidogrel, and 45.3 percent received DAPT. The researchers found that, compared with those on aspirin/clopidogrel or DAPT, patients who did not receive any prehospital antiplatelet therapy had a significantly higher composite of all-cause mortality, , need for revascularization, and stroke within 30 days (38.1 versus 14.9 and 13.9 percent, respectively) and one year (52.4 versus 29.5 and 28.3 percent, respectively). Antiplatelet use remained significantly associated with the primary outcome even after adjustment.

"The findings from the present study have shown that antiplatelet therapy before is associated with a lower rate of major cardiac adverse events, and this remained consistent after multivariate adjustment," the authors write. "This finding suggests that preadmission use of antiplatelet therapy could have protective properties during SVG intervention."

More information: Abstract
Full Text

Related Stories

Aspirin still first-line therapy for unstable angina/NSTEMI

July 17, 2012

(HealthDay) -- Aspirin is still the first line of therapy for patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI), and ticagrelor can be used in place of clopidogrel or prasugrel instead of aspirin ...

Recommended for you

Heart attack treatment hypothesis 'busted'

July 6, 2015

Researchers have long had reason to hope that blocking the flow of calcium into the mitochondria of heart and brain cells could be one way to prevent damage caused by heart attacks and strokes. But in a study of mice engineered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.